Kura Oncology, Inc. (NASDAQ:KURA) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Kura Oncology, Inc. has received a consensus rating of “Moderate Buy” from 15 research firms, with two sell recommendations and ten buy recommendations.
• The stock has a 12-month target price average of $24.67, while its current price is around $9.70, showing potential for significant appreciation.
• Recent insider activity includes COO Kathleen Ford selling 6,892 shares and CEO Troy Edward Wilson buying 50,000 shares, indicating differing confidence levels among executives.

Shares of Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the fifteen research firms that are covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and ten have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $24.6667.

Several research analysts have recently commented on KURA shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Kura Oncology in a report on Saturday. Zacks Research cut shares of Kura Oncology from a "hold" rating to a "strong sell" rating in a report on Tuesday, October 7th. Guggenheim started coverage on shares of Kura Oncology in a report on Thursday, September 4th. They set a "neutral" rating on the stock. HC Wainwright reaffirmed a "buy" rating and set a $40.00 target price on shares of Kura Oncology in a report on Monday, October 20th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $24.00 target price on shares of Kura Oncology in a report on Monday, October 20th.

Insider Activity at Kura Oncology

In other news, COO Kathleen Ford sold 6,892 shares of the firm's stock in a transaction that occurred on Monday, September 29th. The shares were sold at an average price of $8.94, for a total transaction of $61,614.48. Following the transaction, the chief operating officer directly owned 63,375 shares of the company's stock, valued at approximately $566,572.50. This trade represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Troy Edward Wilson acquired 50,000 shares of the firm's stock in a transaction that occurred on Monday, September 8th. The stock was purchased at an average cost of $8.20 per share, for a total transaction of $410,000.00. Following the completion of the purchase, the chief executive officer directly owned 100,968 shares of the company's stock, valued at $827,937.60. The trade was a 98.10% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders sold 78,058 shares of company stock valued at $697,839. 6.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. State of Wyoming acquired a new position in Kura Oncology during the first quarter valued at approximately $48,000. Merit Financial Group LLC acquired a new position in Kura Oncology during the third quarter valued at approximately $89,000. Magnetar Financial LLC acquired a new position in Kura Oncology during the first quarter valued at approximately $79,000. Tower Research Capital LLC TRC raised its position in Kura Oncology by 471.3% during the second quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company's stock valued at $70,000 after purchasing an additional 9,958 shares in the last quarter. Finally, Brighton Jones LLC acquired a new position in Kura Oncology during the third quarter valued at approximately $108,000.

Kura Oncology Stock Up 6.6%

Kura Oncology stock opened at $9.70 on Friday. The stock has a market cap of $841.96 million, a P/E ratio of -4.29 and a beta of 0.32. The company has a quick ratio of 6.16, a current ratio of 6.16 and a debt-to-equity ratio of 0.02. Kura Oncology has a twelve month low of $5.41 and a twelve month high of $19.73. The company's 50-day moving average price is $8.68 and its two-hundred day moving average price is $7.03.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.90). The business had revenue of $15.29 million for the quarter, compared to analysts' expectations of $64.95 million. As a group, analysts expect that Kura Oncology will post -2.44 EPS for the current year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.